Astec Lifesciences (ASTEC) Share Price Falls 8.03% Today to Rs 701.45
- September 10, 2026
- Posted by: Harsh Piplani
- Category: News
Astec Lifesciences Share Price fell to Rs 701.45 on 10 September 2026, down 8.03% or Rs 61.25 from the previous close of Rs 762.70. The move reduced the company’s market capitalisation to Rs 1,476.24 crore and put the stock in focus during the session.
The supplied market data confirms the decline, but it does not identify a company-specific trigger behind it. What is visible is the intraday pattern: the stock opened at Rs 749.05, touched a high of Rs 752.40, and then slipped to a low of Rs 700.05. With turnover at Rs 1.44 crore, the session showed active trading while the price stayed close to the day’s weakest levels.
For readers tracking Astec Lifesciences Share Price today, the key context lies in three areas: short-term price behaviour, technical placement versus moving averages, and a fundamental profile that shows weak profitability despite a relatively elevated price-to-book multiple. Those pieces together matter more than any unverified explanation.
Astec Lifesciences (ASTEC) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 701.45 |
| Previous Close | Rs 762.7 |
| Today's Move | -Rs 61.25 (-8.03%) |
| Open | Rs 749.05 |
| High | Rs 752.4 |
| Low | Rs 700.05 |
| Turnover | Rs 1.44 crore |
| Market Capitalisation | Rs 1,476.24 crore |
| Market Cap Category | Small Cap |
The session opened below the previous close, which immediately signalled weakness. After a brief move to Rs 752.40, the stock gave up ground and moved down toward Rs 700.05. At Rs 701.45, it remained only marginally above the low, suggesting that selling pressure dominated most of the day.
This pattern is useful because it shows more than just the closing gap from the prior session. A stock that opens weak and stays near its intraday low often reflects persistent pressure through the day rather than a brief early dip. The turnover figure of Rs 1.44 crore confirms that the move happened with visible participation, even though the data set does not establish the reason.
Astec Lifesciences Share Price is therefore notable not only for the size of the decline, but also for the structure of the trading session: weak open, recovery, and price holding near the day’s bottom range.
Technical Context: RSI and Moving Averages
The available technical indicators present a mixed setup. The stock’s RSI stands at 76.67, which is elevated. On its own, a high RSI indicates strong recent momentum, but it does not tell investors whether that momentum will continue or cool off. In a session where the stock is down sharply, it instead suggests that the counter had been trading with strong momentum before this decline.
The moving-average picture is also important. The current price of Rs 701.45 remains above the 50-day moving average of Rs 596.03 and above the 200-day moving average of Rs 651.29. That means the stock is still trading above both medium-term and longer-term reference levels, despite today’s fall.
Read together, the indicators show tension rather than a clean signal. On one side, the day’s action is clearly weak. On the other, the stock is still above both the 50-DMA and 200-DMA, while RSI remains elevated at 76.67. For investors watching Astec Lifesciences Share Price, this creates a more nuanced technical picture than the one-day move alone might suggest.
Astec Lifesciences (ASTEC) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,476.24 crore |
| P/B Ratio | 4.57x |
| ROE | -25.88% |
| ROCE | -5.71% |
| EPS | Rs -29.89 |
| Book Value Per Share | Rs 167 |
| Dividend Yield | 0% |
The fundamental picture is weaker than the long-term technical placement. Astec Lifesciences has a price-to-book ratio of 4.57, with book value at Rs 167 per share. That means the stock is trading at a substantial premium to stated book value.
Profitability metrics, however, are negative. ROE is -25.88%, ROCE is -5.71%, and EPS is Rs -29.89. These figures indicate that the company is not currently generating positive returns on shareholder capital or capital employed, based on the supplied data. Dividend yield is 0%, so there is no income buffer in the available snapshot.
This is one of the central points in the current setup. The stock is not being valued like a deep book-value discount case, yet the reported profitability numbers are weak. That mismatch does not prove anything about future performance, but it does help explain why a sharp fall attracts attention quickly.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Chemicals |
| Industry | Pesticides & Agrochemicals |
| Benchmark Scope | same industry |
| Benchmark Median P/E | 20.64x |
| Benchmark Average P/E | 34.74x |
| Benchmark P/E Range | 10.24x to 311.22x |
| Company P/B Ratio | 4.57x |
| Benchmark Median P/B | 1.97x |
| Benchmark Average P/B | 2.47x |
| Company ROE | -25.88% |
| Benchmark Median ROE | 10.92% |
| Benchmark Average ROE | 8.48% |
| Company ROCE | -5.71% |
| Benchmark Median ROCE | 13.1% |
| Benchmark Average ROCE | 12.24% |
| Company Market Capitalisation | Rs 1,476.24 crore |
| Benchmark Median Market Cap | Rs 1,080.75 crore |
| Benchmark Average Market Cap | Rs 4,960.82 crore |
Astec Lifesciences operates in the Chemicals sector within the Pesticides & Agrochemicals industry. Across 34 benchmark companies in the same industry, the median market capitalisation is Rs 1,080.75 crore and the average is Rs 4,960.82 crore. At Rs 1,476.24 crore, the company sits above the median but below the average.
On valuation, its P/B ratio of 4.57 is above the industry median of 1.97 and average of 2.47. The benchmark P/E data spans from 10.24 to 311.22 across 29 companies, with a median of 20.64 and an average of 34.
The profitability gap is clearer. Astec’s ROE of -25.88% is well below the industry median of 10.92% and average of 8.48%. Its ROCE of -5.71% is also below the industry median of 13.1% and average of 12.24%. In simple terms, the company is currently trailing the wider peer group on return metrics while trading above typical industry P/B levels.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| UPL | UPL | 48,624.15 | 24.11 | 1.4 | 6.95 | 12 |
| PI Industries | PIIND | 36,271.25 | 31.2 | 3.17 | 12.35 | 16 |
| Sumitomo Chemical India | SUMICHEM | 24,290.93 | 41.48 | 6.67 | 17.26 | 23.39 |
| Bayer CropScience | BAYERCROP | 17,909.87 | 24.24 | 5.4 | 23.7 | 30.08 |
| Sharda Cropchem | SHARDACROP | 7,188.77 | 11.28 | 2.19 | 24.16 | 31.1 |
The listed peer set reinforces that contrast. Astec is smaller than UPL, PI Industries, Sumitomo Chemical India, Bayer CropScience, and Sharda Cropchem on market value. More importantly, all five named peers show positive ROE and ROCE, while Astec’s return ratios are negative in the supplied snapshot.
On P/B, Astec at 4.57 is above UPL at 1.4, PI Industries at 3.17, and Sharda Cropchem at 2.19, but below Sumitomo Chemical India at 6.67 and Bayer CropScience at 5.4. That means it is not the lowest-valued stock in the peer set on a book-value basis, even though its profitability trails these companies.
Astec Lifesciences Share Price is therefore being judged against a peer group where scale and return metrics are generally stronger. That is a useful benchmark when evaluating whether the current decline is simply a one-day move or part of a broader repricing discussion in the market.
Why Investors Are Watching Astec Lifesciences
- The stock fell 8.03% to Rs 701.45 and remained close to the day’s low of Rs 700.05.
- It is still above its 50-DMA of Rs 596.03 and 200-DMA of Rs 651.29.
- RSI at 76.67 indicates elevated momentum in the recent trend.
- P/B stands at 4.57, while ROE, ROCE, and EPS are negative in the supplied data.
- Industry benchmark figures show return ratios well below sector medians and averages.
About Astec Lifesciences
Astec Lifesciences is classified under the Chemicals sector and the Pesticides & Agrochemicals industry. In market comparisons, it sits within a listed peer universe that includes larger companies such as UPL, PI Industries, Sumitomo Chemical India, Bayer CropScience, and Sharda Cropchem.
That industry classification matters because it gives investors a standard comparison set for valuation, profitability, and market-cap positioning. When a sharp session move occurs, those benchmark numbers help place it in context without assuming a cause that the data does not provide.
Track Astec Lifesciences Share Price on Univest
UseAstec Lifesciences (ASTEC) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
Investors following Astec Lifesciences Share Price can monitor price updates, moving averages, RSI, valuation ratios, market-cap changes, and sector comparisons on Univest. Those reference points can help frame whether the latest move reflects only intraday pressure or a broader change in how the market is viewing the stock.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Astec Lifesciences Share Price falling today?
Ans. The stock is down 8.03% at Rs 701.45 compared with the previous close of Rs 762.70. The supplied data confirms the decline, but it does not identify a company-specific catalyst.
What is Astec Lifesciences Share Price today?
Ans. Astec Lifesciences Share Price today is Rs 701.45 as of the supplied update time. The previous close was Rs 762.7. The stock moved 8.03% lower during the session. The intraday range extended from Rs 700.05 to Rs 752.4.
What is the company’s market capitalisation?
Ans. Astec Lifesciences has a market capitalisation of Rs 1,476.24 crore and falls in the Small Cap category. The company operates in the Chemicals sector. ROE is -25.88% and ROCE is -5.71%.
How does it compare with the industry benchmark?
Ans. Its P/B of 4.57 is above the industry median of 1.97 and average of 2.47, while its ROE and ROCE are below the industry median and average return levels. The stock belongs to the Chemicals sector.
How does it compare with listed peers?
Ans. Compared with peers such as UPL, PI Industries, Sumitomo Chemical India, Bayer CropScience, and Sharda Cropchem, Astec is smaller in market value and weaker on ROE and ROCE, while its P/B is above several peers.
